Immunome, Inc.

IMNM · United States

Share price · IMNM

$16.78-10.78 (-39.11%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.4M (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when IMNM's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 2 Nov 2026+7.6%
  2. 13 Oct 2026-8.2%

    Nothing announced by IMNM that day or the session before.

  3. 6 Oct 2026-8.8%
  4. 24 Sep 2026-7.8%
  5. 12 Aug 2026+6.6%
  6. 4 Aug 2026+8.9%
  7. 2 Jul 2026+9.9%
  8. 22 May 2026-5.7%
  9. 21 May 2026+6.6%
  10. 20 May 2026+9.5%

Share of unusual movement by asset

For each asset, the share of IMNM's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Varegacestat
events and moves
4shown from 8 days
IM-1021
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—6%
Other company news (earnings, financing, releases naming no asset)—9%
Sessions with no dated event—85%

Assets

(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 2/3
Gamma-secretase (presenilin complex)Small molecule
Soft Tissue Sarcoma
Desmoid Tumors
Phase 1
ROR1Antibody–drug conjugate
Solid Tumors
Advanced ROR1-Expressing Solid Tumors and Lymphomas
Phase 1
Undisclosed / early pipelineAntibody–drug conjugate
Non-Small Cell Lung Cancer

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

28 April 2027FDA action datevaregacestat (AL102)PDUFA target action date for the varegacestat NDA
US, FDA · FDA · Source ↗

Recent

30 October 2026Filing acceptedVaregacestatEMA validates the varegacestat MAA in desmoid tumors
EU, EMA · Source ↗
8 July 2026Filing acceptedvaregacestat (AL102)FDA accepts the NDA for varegacestat in desmoid tumors
US, FDA · Immunome, Inc. · Source ↗
15 December 2025Topline resultvaregacestat (AL102)Phase 3 RINGSIDE meets primary endpoint of progression-free survival
Immunome, Inc. · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0$70M$213M+ $249M short-term inv.$86M-$61M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$60M$218M+ $302M short-term inv.$73M-$62M operating cash flowreport ↗
2026-Q1$0$46M$583M$54M-$59M operating cash flowreport ↗
2025-Q3$0$49M$273M+ $0 short-term inv.$57M-$41M operating cash flowreport ↗
2025-Q2$4.0M$40M$144M+ $124M short-term inv.$43M-$49M operating cash flowreport ↗
2025-Q1$2.9M$37M$258M+ $60M short-term inv.$42M-$53M operating cash flowreport ↗
2024-Q3$2.9M$37M$156M+ $85M short-term inv.$47M-$34M operating cash flowreport ↗
2024-Q2$2.4M$29M$165M+ $113M short-term inv.$36M-$23M operating cash flowreport ↗
2024-Q1$1.0M$15M$270M+ $40M short-term inv.$129M-$11M operating cash flowreport ↗
2023-Q3$3.6M$3.8M$91M$4.3M-$8.6M operating cash flowreport ↗
2023-Q2$4.3M$5.7M$39M$5.6M-$5.7M operating cash flowreport ↗
2023-Q1$2.4M$3.9M$45M$4.3M$24M operating cash flowreport ↗
2022-Q3—$5.2M$27M$8.5M-$7.6M operating cash flowreport ↗
2022-Q2—$5.7M$35M$8.9M-$8.1M operating cash flowreport ↗
2022-Q1—$8.1M$43M$12M-$6.4M operating cash flowreport ↗
2021-Q3—$4.5M$56M$7.7M-$4.1M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$6.9M$177M$654M+ $0 short-term inv.$53M-$191M operating cash flowreport ↗

Immunome reported full-year 2025 revenue of $6.94M, down 23.2% YoY, with an R&D spend of $177.29M, up 36.9% YoY. Cash and equivalents totaled $653.69M, and the company posted a net loss of $212.39M.

Management expects current cash to fund operations into 2028. An NDA submission for varegacestat in desmoid tumors is planned for 2Q 2026 following positive Phase 3 RINGSIDE results, initial IM-1021 data are expected in 2026, and three IND submissions for solid tumor-targeted ADC programs are planned during the year. A December 2025 underwritten public offering raised $460.5M in gross proceeds.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$9.0M$130M$143M+ $74M short-term inv.$73M-$111M operating cash flowreport ↗
2023-FY$14M$23M$99M+ $39M short-term inv.$27M-$7.6M operating cash flowreport ↗
2022-FY—$23M$20M$9.2M-$29M operating cash flowreport ↗
2021-FY—$14M$49M$6.2M-$18M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 11 purchases ($2.3M), 28 sales ($27.5M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-11Higgins Jack · Chief Scientific OfficerOption exercise18,000$1.35$24KForm 4
2026-09-11Higgins Jack · Chief Scientific OfficerOpen-market sale13,200$25.32$334KForm 4
2026-09-11Higgins Jack · Chief Scientific OfficerGift8,800——Form 4
2026-09-11Higgins Jack · Chief Scientific OfficerOption exercise (derivative)18,000——Form 4
2026-08-12Barchas Isaac · directorOpen-market sale11,048$27.25$301KForm 4
2026-08-11Barchas Isaac · directorOpen-market sale62,291$26.23$1.6MForm 4
2026-08-10Barchas Isaac · directorOpen-market sale10,125$26.07$264KForm 4
2026-08-07Barchas Isaac · directorOpen-market sale15,248$26.06$397KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 199 reporting institutions held 116.7M shares ($2.1B, 98.8% of shares outstanding).

#InstitutionSharesValue
1FMR LLC16,969,954$371.1M
2BlackRock, Inc.8,168,674$178.6M
3Redmile Group, LLC5,558,885$121.6M
4STATE STREET CORP5,399,901$118.1M
5PRIMECAP MANAGEMENT CO/CA/4,788,231$104.7M
6WELLINGTON MANAGEMENT GROUP LLP4,731,977$103.5M
7VANGUARD CAPITAL MANAGEMENT LLC4,429,697$96.9M
8Driehaus Capital Management LLC4,099,901$89.7M
9ENAVATE SCIENCES GP, LLC3,613,799$79.0M
10MORGAN STANLEY2,841,589$62.1M
11GEODE CAPITAL MANAGEMENT, LLC2,560,664$56.0M
12JPMORGAN CHASE & CO2,777,836$53.6M
13SILVERARC CAPITAL MANAGEMENT, LLC1,850,278$40.5M
14Sofinnova Investments, Inc.1,701,904$37.2M
15Woodline Partners LP1,575,398$34.5M